In various rodent models of type-2 diabetes, treatment with thiazolidinedione (TZD) PPAR-γ agonists such as troglitazone, ciglitazone, pioglitazone and rosiglitazone are suggested to improve insulin resistance and glycemic control. Here, PPARG is linked to Insulin resistance.